Featured Publications
Annual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading cause
2017
Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder
Adams TG, Bloch MH, Pittenger C. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 269-271. PMID: 28121735, PMCID: PMC5321820, DOI: 10.1097/jcp.0000000000000659.Peer-Reviewed Original ResearchPredictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder
Reed MO, Jakubovski E, Johnson JA, Bloch MH. Predictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 296-309. PMID: 28253029, PMCID: PMC5439457, DOI: 10.1089/cap.2015.0168.Peer-Reviewed Original Research
2016
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorder
2015
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatment
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomesPharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C, Bloch MH. Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2014, 37: 375-391. PMID: 25150568, PMCID: PMC4143776, DOI: 10.1016/j.psc.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyDrug Therapy, CombinationHumansNonprescription DrugsObsessive-Compulsive DisorderPrecision MedicinePsychotherapyPsychotropic DrugsConceptsObsessive-compulsive disorderPharmacological treatmentLow-dose neuroleptic medicationsSelective serotonin reuptake inhibitorsProfound clinical challengeSecond-line treatmentSerotonin reuptake inhibitorsSignificant symptomatic reliefTricyclic clomipramineAppropriate pharmacotherapyNeuroleptic medicationReuptake inhibitorsSubstantial morbiditySymptomatic reliefAvailable treatmentsClinical challengeHigh dosesOCD refractoryTreatmentDisordersMedicationsMorbidityPharmacotherapyPatientsClomipramine
2012
D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.
Bontempo A, Panza KE, Bloch MH. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. The Journal Of Clinical Psychiatry 2012, 73: 533-7. PMID: 22579153, PMCID: PMC3625928, DOI: 10.4088/jcp.11r07356.Peer-Reviewed Original ResearchAnti-Anxiety AgentsAnxiety DisordersBehavior TherapyCombined Modality TherapyCycloserineHumansTreatment Outcome
2004
Paraneoplastic Limbic Encephalitis: Ovarian Cancer Presenting as an Amnesic Syndrome
Bloch MH, Hwang WC, Baehring JM, Chambers SK. Paraneoplastic Limbic Encephalitis: Ovarian Cancer Presenting as an Amnesic Syndrome. Obstetrics And Gynecology 2004, 104: 1174-1177. PMID: 15516442, DOI: 10.1097/01.aog.0000128110.31784.c8.Peer-Reviewed Original ResearchMeSH KeywordsAmnesiaBiopsy, NeedleCombined Modality TherapyCystadenocarcinoma, PapillaryDiagnosis, DifferentialFemaleFollow-Up StudiesHumansImmunohistochemistryImmunotherapyLimbic EncephalitisMiddle AgedNeoplasm StagingOvarian NeoplasmsOvariectomyParaneoplastic SyndromesPlasmapheresisRisk AssessmentTreatment OutcomeConceptsParaneoplastic limbic encephalitisShort-term memory lossLimbic encephalitisOvarian cancerMemory lossInitiation of plasmapheresisLimbic system abnormalitiesRare neurologic manifestationDramatic clinical improvementPrompt surgical managementTomography scan findingsEpithelial ovarian cancerClinical improvementNeurologic manifestationsRare complicationScan findingsSurgical managementOvarian tumorsPrimary tumorTesticular cancerSystem abnormalitiesEncephalitisAmnesic syndromeCancerPlasmapheresis